Interviews

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, MD, PhD.

Managed care will continue to evolve and employers and policy makers have a responsibility to understand how to best serve their patients, according to John Michael O'Brien, PharmD, MPH.

Artificial intelligence (AI) has the potential to deliver personalized nutrition; however, there is a need for professional oversight, emphasized Julia Logan, BS.

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and improved patient quality of life.

Julia Logan, BS, discusses the vital role of nutrition in cancer care, highlighting how artificial intelligence can enhance dietary recommendations for patients.

Luis Carvajal-Carmona, PhD, stresses the importance of global collaboration in cancer research to enhance understanding and treatment across diverse populations.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world care for patients with resectable head and neck cancer.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck cancer treatment.

Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the safety, reliability, and effectiveness of rusfertide to treat polycythemia vera.

John Michael O'Brien, PharmD, MPH, discussed the changes in managed care over the past 30 years to commemorate the 30th anniversary of The American Journal of Managed Care®.

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

Richard J. Nowak, MD, MS, Yale School of Medicine, explains what some early myasthenia gravis symptoms are and their impact on research efforts.

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

Christine Funke, MD, discusses how the treatment of glaucoma has evolved in her decade of experience.

Program chairs Lillian L. Siu, MD, FAACR, and Matthew G. Vander Heiden, MD, PhD, highlight the cross-disciplinary approach to cancer research and innovation being taken at this year's American Association for Cancer Research (AACR) Annual Meeting.

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake trends in commercial claims data.

Although immunotherapies and biomarker-driven interventions have transformed lung cancer outcomes, Martin Edelman, MD, Fox Chase Cancer Center, highlighted the present challenge hindering clinicians' abilities to anticipate patients' treatment responses.

Benjamin K. Chen, MD, PhD, discussed the next steps after the results of his study in genetic tagging showed promise in targeting HIV cells.

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design of the ALPH and ALPHA2 trials, which are investigating the chimeric antigen receptor T-cell therapy (CAR T) cemacabtagene ansegedleucel (cema-cel) in relapsed/refractory large B-cell lymphoma.

Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.

Sam Peasah, PhD, MBA, RPh, director of High-Value Health Care Value-Based Pharmacy Initiatives at UPMC Health Plan, discusses ways that health plans can help reduce the cost burden of medications to improve adherence.

Pierluigi Porcu, MD, speaks to the considerations clinicians need to account for to balance cost, patient experience, and outcomes for those with chronic lymphocytic leukemia (CLL).

Benjamin Chen, MD, PhD, of the Icahn School of Medicine at Mount Sinai, discusses the implications of his new study involving genetically tagging immune cells with latent HIV.

Employers have a unique role in helping to close health equity gaps among employees and their families, explained Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council.

Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address patients' cirrhosis, explained Naim Alkhouri, MD.

Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.

Erin Weber, MS, CAQH, is hopeful that artificial intelligence (AI) will empower people rather than replace them.

JC Scott, CEO and president of The Pharmaceutical Care Management Association, discusses current efforts in increasing biosimilar adoption and pharmacy benefit manager (PBM) reform.

Marla Black Morgan, MD, with Phoebe Neurology Associates, presented findings on a study into the diagnostic journey of patients with neuromuscular conditions who have rare diseases at the 2025 American Academy of Neurology annual meeting.